UNSPSC 51172902: Acetic acid/oxyquinoline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.

UNSPSC 51172902 Acetic acid/oxyquinoline (Commodity) covers chemical supply for water treatment and facility operations at municipal and state health-care institutions, though the code's abstract name diverges significantly from the concrete work being solicited. The City of Meriden's recent IFB for sodium bisulfite (B027-15, due July 29, 2026) exemplifies the actual scope: municipalities procure industrial and treatment chemicals for water pollution control facilities on a unit-cost basis, with standard municipal insurance and bonding requirements. A parallel RFP from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicited generic pharmaceuticals and OTC products for state and local facilities across multiple jurisdictions including Oregon—a broader therapeutic and supply-chain scope that reflects state-level and cooperative purchasing activity in chemical and pharmaceutical commodities. Issuing bodies include city water departments and state health authorities procuring through direct RFB and cooperative purchasing vehicles; the MMCAP opportunity signals that multi-state cooperative agreements are active in this commodity space.

Recent activity concentrates in Connecticut and Minnesota. The City of Meriden's water treatment chemical procurement (due July 29, 2026) represents direct municipal procurement with firm pricing and performance/payment bonds required. The MMCAP RFP (due March 26, 2026; questions closed February 18, 2026; awards effective July 1, 2026) is substantially larger in scope, establishing multi-vendor, multi-state supply agreements for pharmaceutical and OTC products through three authorized wholesalers (Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC) with a two-year term and 3 percent administrative fee. MMCAP awards will be sole, dual, or multi-award based on therapeutic and availability considerations. Neither opportunity discloses a specific contract value or budget ceiling, and the MMCAP RFP does not identify set-aside or disadvantaged-enterprise restrictions in available documentation. Vendors in the pharmaceutical track must certify cGMP and DSCSA compliance and maintain relationships with at least two of the three authorized wholesalers.